Hind Pharma Agencies Profile
Key Indicators
- Authorised Capital ₹ 7.60 M
as on 31-12-2024
- Paid Up Capital ₹ 7.60 M
as on 31-12-2024
- Company Age 3 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.00 M
as on 31-12-2024
- Revenue %
(FY 2023)
- Profit 7940.15%
(FY 2023)
- Net Worth 11335.04%
(FY 2023)
- Total Assets 49822.59%
(FY 2023)
About Hind Pharma Agencies
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.60 M and a paid-up capital of Rs 7.60 M.
The company currently has active open charges totaling ₹8.00 M.
Gogi George, Manikandan Parasuraman, and Samson John serve as directors at the Company.
- CIN/LLPIN
U85110KL2021PTC072482
- Company No.
072482
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Nov 2021
- Date of AGM
28 Nov 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Kottayam, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Hind Pharma Agencies?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gogi George  | Director | 19-Mar-2022 | Current |
| Manikandan Parasuraman | Additional Director | 14-Nov-2023 | Current |
| Samson John | Additional Director | 12-Aug-2022 | Current |
Financial Performance of Hind Pharma Agencies.
Hind Pharma Agencies Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 7940.15% increase in profit. The company's net worth Soared by an impressive increase of 11335.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Hind Pharma Agencies?
Unlock access to Hind Pharma Agencies's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
₹8.00 M
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 0.80 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Aug 2023 | Axis Bank Limited | ₹8.00 M | Open |
How Many Employees Work at Hind Pharma Agencies?
Hind Pharma Agencies has a workforce of 0 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hind Pharma Agencies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hind Pharma Agencies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
